KRAS and neoplasm: Furthermore, the implications of this study extend well beyond KRASG12C‐mutant LUAD, challenging the ‘one‐size‐fits‐all’ approach to KRAS‐driven cancers and paving the way for biomarker and TME‐driven combinatorial therapies that address the complex, multifaceted nature of KRAS‐mutant tumours.